0000000001268627

AUTHOR

G. Marrazzo

showing 3 related works from this author

Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use

2020

Abstract Psychotic patients with a lifetime history of cannabis use generally show better cognitive functioning than other psychotic patients. Some authors suggest that cannabis-using patients may have been less cognitively impaired and less socially withdrawn in their premorbid life. Using a dataset comprising 948 patients with first-episode psychosis (FEP) and 1313 population controls across 6 countries, we examined the extent to which IQ and both early academic (Academic Factor [AF]) and social adjustment (Social Factor [SF]) are related to the lifetime frequency of cannabis use in both patients and controls. We expected a higher IQ and a better premorbid social adjustment in psychotic p…

MalecognitionIntelligenceComorbiditySUBSTANCE USE DISORDERS0302 clinical medicineSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.MedicinePREDICTORSRISKeducationeducation.field_of_studybiologyCognitionMiddle AgedPsychosocial FunctioningsociabilityPsychiatry and Mental healthSchizophreniaFemaleMarijuana UseSocial AdjustmentMENTAL-HEALTHAdultmedicine.medical_specialtyPsychosisAdolescentPopulation1ST EPISODEDRUG-USEpreillnessSettore MED/01 - Statistica MedicaYoung Adult03 medical and health sciencesAGESettore M-PSI/08 - Psicologia ClinicaHumansCognitive skilleducationPsychiatrySettore MED/25 - Psichiatriabusiness.industryCase-control studypreillnebiology.organism_classificationmedicine.diseaseEDUCAÇÃO030227 psychiatryschizophreniaPsychotic DisordersCase-Control StudiesONSETCannabisNEUROCOGNITIONbusinessmarijuanaNeurocognitive030217 neurology & neurosurgeryRegular ArticlesSchizophrenia Bulletin
researchProduct

Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

2021

Background: No uniform criteria for a sensitive identification of the transition from relapsing–remitting multiple sclerosis (MS) to secondary-progressive multiple sclerosis (SPMS) are available. Objective: To compare risk factors of SPMS using two definitions: one based on the neurologist judgment (ND) and an objective data-driven algorithm (DDA). Methods: Relapsing-onset MS patients ( n = 19,318) were extracted from the Italian MS Registry. Risk factors for SPMS and for reaching irreversible Expanded Disability Status Scale (EDSS) 6.0, after SP transition, were estimated using multivariable Cox regression models. Results: SPMS identified by the DDA ( n = 2343, 12.1%) were older, more disa…

Oncologymedicine.medical_specialtyRelapsing-RemittingMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineDisease registryRecurrenceRisk Factorsbig dataInternal medicinemedicineHumansdata-driven algorithmMultiple sclerosi030212 general & internal medicinebig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressive; Disease Progression; Humans; Recurrence; Risk Factors; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-RemittingSecondary progressiveTransition (genetics)business.industryMultiple sclerosisMultiple Sclerosis Chronic Progressivemedicine.diseaseChronic ProgressiveNeurologybig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressiveDisease Progressiondisease registrysecondary progressiveSettore MED/26 - NeurologiaNeurology (clinical)prognosisbusinessprognosi030217 neurology & neurosurgery
researchProduct

Quality of life, alexithymia, and defence mechanisms in patients affected by breast cancer across different stages of illness

2016

Objectives: The aim of this study was to evaluate the effect of alexithymia and defence mechanisms on the quality of life of patients affected by breast cancer at different stages of the disease. Methods A convenience sample of 110 patients with breast cancer was involved in the study: 41 were receiving adjuvant chemotherapyafter surgery, 29 had disease-free survival in follow-up and 40 were receiving chemotherapy for metastatic disease. Quality of life, alexithymia and defence mechanisms were assessed using the following instruments: EORTC QLQ-C30-BR23, Toronto Alexithymia Scale (TAS-20) and Defense Mechanism Inventory (DMI). Results Compared to the other groups, patients receiving chemoth…

Settore MED/06 - Oncologia MedicaSettore M-PSI/08 - Psicologia ClinicaSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.Psycho-oncology Quality of Life Alexithymia Defence mechanismsBreast CanceSettore MED/25 - Psichiatria
researchProduct